Enterovirus 71 Infection
Conditions
Brief summary
Subjects will receive the first IM injection of study vaccine on Day 1 and will receive a second dose 56 days later. A booster vaccine will be given 365 days after the first dose in subjects 2 months to \< 2 years of age. The last study visit is on Day 422 when subjects will be contacted via telephone / home visit system to assess for adverse events and concomitant medications.
Interventions
BIOLOGICALEV71vac
Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
BIOLOGICALPlacebo
Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
Sponsors
Medigen Vaccine Biologics Corp.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
2 Months to 6 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy children and infants aged from 2 months to less than 6 years as established by medical history and clinical examination. 2. The subjects' parents/guardians are able to understand and sign the ICF.
Exclusion criteria
1. Age \< 2 months or ≥ 6 years. 2. For subjects \< 1 year, gestational age \< 34 weeks or birth weight \< 2200 grams. 3. Has poor venous access (for subjects in sub-study only). 4. Currently has a fever defined as ear/rectal temperature ≥ 38°C or axillary temperature ≥ 37.5 °C within 2 days before the time of planned vaccination. 5. Has had previous known exposure to EV71 or has received EV71 vaccine. 6. Has a history of herpangina or HFMD associated with enterovirus infection in the past 30 days before the date of the planned study drug vaccination. 7. Has been diagnosed with a significant neurological, pulmonary, cardiovascular, hematological, hepatic, or renal disorder. 8. Has a history of hypersensitivity to vaccines, or a history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. 9. Has used any investigational/non-registered product (including drug, vaccine, or invasive medical device) within 28 days before vaccination or plan to use during the study period. 10. Has confirmed or suspected autoimmune disorder, or immunodeficiency. 11. Administration of any licensed live attenuated vaccine within 14 days before or after each study vaccination (with the exceptions of live attenuated Rotavirus vaccine via oral route). 12. Has used immunoglobulins or any blood products within 11 months before vaccination or plan to use during the whole study period. 13. Has had immunosuppressants, cytotoxic drugs, corticosteroids (including prednisolone ≥ 0.5 mg/kg/day or equivalent), or immunomodulators taken for \> 14 days within 6 months before first vaccination or plan to use before the last scheduled study visit. (Inhaled and topical steroids are allowed). 14. Has any medical or psychiatric condition, that is a contraindication to protocol participation based on the judgment of the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Laboratory Confirmed EV71-Associated Disease | Approximately 14 months | The primary outcome is the number of Laboratory confirmed EV71-associated disease by viral isolation or CODEHOP assay. |
Countries
Taiwan, Vietnam
Outcome results
None listed